Juan Wang

Dr. Juan Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in Current Atherosclerosis Reports
Verified
Journal Article
Open access
PDF file
JWJuan Wang
Juan Wang
QWQiang Wu
Qiang Wu
XWXinyu Wang
Xinyu Wang
HLHongbin Liu
Hongbin Liu
MCMulei Chen
Mulei Chen
JZJiu-Chang Zhong
Jiu-Chang Zhong
Purpose of the review Macrophage accumulation and activation function as hallmarks of atherosclerosis and have complex and intricate dynamics throughout all components and stages of atherosclerotic plaques. In this review, we focus on the regulatory roles and underlying mechanisms of macrophage phenotypes and metabolism in atherosclerosis. We highlight the diverse range of macrophage phenotypes present in atherosclerosis and their potential roles in progression and regression of atherosclerotic plaque. Furthermore, we discuss the challenges and opportunities in developing therapeutic strategies for preventing and treating atherosclerotic cardiovascular disease. Recent findings Dysregulation of macrophage polarization between the proinflammatory M1 and anti-inflammatory M2 phenotypealters the immuno-inflammatory response during atherosclerosis progression, leading to plaque initiation, growth, and ultimately rupture. Altered metabolism of macrophage is a key feature for their function and the subsequent progression of atherosclerotic cardiovascular disease. The immunometabolism of macrophage has been implicated to macrophage activation and metabolic rewiring of macrophages within atherosclerotic lesions, thereby shifting altered macrophage immune-effector and tissue-reparative function. Summary, Insights and Perspective Targeting macrophage phenotypes and metabolism are potential therapeutic strategies in the prevention and treatment of atherosclerosis and atherosclerotic cardiovascular diseases. Understanding the precise function and metabolism of specific macrophage subsets and their contributions to the composition and growth of atherosclerotic plaques could reveal novel strategies to delay or halt development of atherosclerotic cardiovascular diseases and their associated pathophysiological consequences. Identifying biological stimuli capable of modulating macrophage phenotypes and metabolism may lead to the development of innovative therapeutic approaches for treating patients with atherosclerosis and coronary artery diseases. Graphical Abstract

23 August 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JWJuan Wang
Juan Wang
JWJing Wang
Jing Wang
JZJiu-Chang Zhong
Jiu-Chang Zhong
HLHongbin Liu
Hongbin Liu
WLWeiming Li
Weiming Li
XWXiaodong Wang
Xiaodong Wang
Atherosclerosis is a chronic inflammatory disease of the arterial wall characterized by the accumulation of cholesterol-rich lipoproteins in macrophages. How macrophages commit to proinflammatory polarization under atherosclerosis conditions is not clear. Report here that the level of a circulating protein, leucine-rich alpha-2 glycoprotein 1 (LRG1), is elevated in the atherosclerotic tissue and serum samples from patients with coronary artery disease (CAD). LRG1 stimulated macrophages to proinflammatory M1-like polarization through the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK) pathways. The LRG1 knockout mice showed significantly delayed atherogenesis progression and reduced levels of macrophage-related proinflammatory cytokines in a high-fat diet–induced Apoe −/− mouse atherosclerosis model. An anti-LRG1 neutralizing antibody also effectively blocked LRG1-induced macrophage M1-like polarization in vitro and conferred therapeutic benefits to animals with ApoE deficiency-induced atherosclerosis. LRG1 may therefore serve as an additional biomarker for CAD and targeting LRG1 could offer a potential therapeutic strategy for CAD patients by mitigating the proinflammatory response of macrophages.

1 July 2023 in Journal of Geriatric Cardiology
Verified
Journal Article
Open access
PDF file
JWJuan Wang
Juan Wang
LHLi-Na Han
Li-Na Han
DADao-Sheng Ai
Dao-Sheng Ai
XWXin-Yu Wang
Xin-Yu Wang
WZWan-Jing Zhang
Wan-Jing Zhang
MCMulei Chen
Mulei Chen
BACKGROUNDGrowth differentiation factor 15 (GDF-15) has been explored as a potential biomarker for various inflammatory diseases and cardiovascular events. This study aimed to assess the predictive role of GDF-15 levels in cardiovascular events and all-cause mortality, considering traditional risk factors and other biomarkers. METHODS A prospective study was conducted and 3699 patients with stable coronary artery disease (CAD) were enrolled into the research. Baseline GDF-15 levels were measured. Median follow-up was 3.1 years during the study. We analyzed clinical variables and several biomarkers. Multivariable Cox regression analysis was performed to evaluate prognostic performance of GDF-15 levels in predicting myocardial infarction (MI), heart failure, stroke, cardiovascular death, and non-cardiovascular death. RESULTSBaseline GDF-15 levels for 3699 patients were grouped by quartile (≤ 1153, 1153–1888, 1888–3043, > 3043 ng/L). Higher GDF-15 levels were associated with older age, male gender, history of hypertension, and elevated levels of N-terminal pro B-type natriuretic peptide (NT-pro BNP), soluble suppression of tumorigenesis-2 (sST2), and creatine (each with P < 0.001). Adjusting for established risk factors and biomarkers in Cox proportional hazards models, a 1 standard deviation (SD) increase in GDF-15 was associated with elevated risk of clinical events [hazard ratio (HR) = 2.18, 95% confidence interval (CI): (1.52–3.11)], including: MI [HR = 2.83 95% CI: (1.03–7.74)], heart failure [HR = 2.71 95% CI: (1.18–6.23)], cardiovascular and non-cardiovascular death [HR = 2.48, 95% CI (1.49–4.11)] during the median follow up of 3.1 years. CONCLUSIONSHigher levels of GDF-15 consistently provides prognostic information for cardiovascular events and all cause death, independent of clinical risk factors and other biomarkers. GDF-15 could be considered as a valuable addition to future risk prediction model in secondary prevention for predicting clinical events in patient with stable CAD.

1 July 2025 in Journal of Geriatric Cardiology
Verified
Journal Article
Open access
PDF file
ZZZhi-Yong Zhang
Zhi-Yong Zhang
XWXin-Yu Wang
Xin-Yu Wang
CHCong-Cong Hou
Cong-Cong Hou
HLHong-Bin Liu
Hong-Bin Liu
LLLyu Lyu
Lyu Lyu
JWJuan Wang
Juan Wang
Background Biomarkers-based prediction of long-term risk of acute coronary syndrome (ACS) is scarce. We aim to develop a risk score integrating clinical routine information (C) and plasma biomarkers (B) for predicting long-term risk of ACS patients. Methods We included 2729 ACS patients from the OCEA (Observation of cardiovascular events in ACS patients). The earlier admitted 1910 patients were enrolled as development cohort; and the subsequently admitted 819 subjects were treated as validation cohort. We investigated 10-year risk of cardiovascular (CV) death, myocardial infarction (MI) and all cause death in these patients. Potential variables contributing to risk of clinical events were assessed using Cox regression models and a score was derived using main part of these variables. Results During 16,110 person-years of follow-up, there were 238 CV death/MI in the development cohort. The 7 most important predictors including in the final model were NT-proBNP, D-dimer, GDF-15, peripheral artery disease (PAD), Fibrinogen, ST-segment elevated MI (STEMI), left ventricular ejection fraction (LVEF), termed as CB-ACS score. C-index of the score for predication of cardiovascular events was 0.79 (95% CI: 0.76−0.82) in development cohort and 0.77 (95% CI: 0.76−0.78) in the validation cohort (5832 person-years of follow-up), which outperformed GRACE 2.0 and ABC-ACS risk score. The CB-ACS score was also well calibrated in development and validation cohort (Greenwood-Nam-D’Agostino: P = 0.70 and P = 0.07, respectively). ConclusionsCB-ACS risk score provides a useful tool for long-term prediction of CV events in patients with ACS. This model outperforms GRACE 2.0 and ABC-ACS ischemic risk score.

Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
PSPuhan Song
Puhan Song
MZMengyi Zheng
Mengyi Zheng
YJYanyao Jia
Yanyao Jia
JWJuan Wang
Juan Wang
JCJing Cheng
Jing Cheng
Background: The triglyceride–glucose (TyG) index is a simple surrogate marker of insulin resistance (IR) and has been associated with coronary artery disease (CAD). However, the association between the TyG index and coronary chronic total occlusion (CTO) remains limited. Methods: In this retrospective study, 1157 patients who underwent coronary angiography at Beijing Chaoyang Hospital from January 2024 to January 2026 were enrolled and classified into the CTO group (n = 317) and the non-CTO group (n = 840). Multivariable logistic regression analyses were performed to assess the association between the TyG index and CTO. Restricted cubic spline analysis was used to examine the linear dose–response relationship. Subgroup analyses were conducted according to age, sex, smoking status, hypertension, and diabetes mellitus. Results: Patients with CTO had a significantly higher TyG index than those without CTO (8.98 [8.46, 9.45] vs. 8.79 [8.41, 9.26], p = 0.003). In the multivariable logistic regression analysis, the TyG index was independently associated with the presence of CTO (OR = 1.377, 95% CI 1.082–1.752, p = 0.009). In a sensitivity analysis further adjusted for diabetes mellitus, the association remained significant (OR = 1.356, 95% CI 1.052–1.747, p = 0.018). Restricted cubic spline curve analysis showed a nonlinear dose–response relationship (p for nonlinear = 0.005) between the TyG index and CTO risk. In the subgroup analyses, the association was directionally consistent across subgroups. Nominally significant associations were observed in elderly participants (OR 1.68, 95% CI 1.20–2.37, p = 0.003), men (OR 1.40, 95% CI 1.06–1.86, p = 0.018), and patients with hypertension (OR 1.55, 95% CI 1.14–2.11, p = 0.005). Conclusions: An elevated TyG index was independently associated with the presence of CTO. The association was generally consistent across major clinical subgroups, with no significant interactions observed.

5 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JWJuan Wang
Juan Wang
KLKuibao Li
Kuibao Li
YLYuanhanyu Luo
Yuanhanyu Luo
XWXinyu Wang
Xinyu Wang
CHCongcong Hou
Congcong Hou
AQAijuan Qu
Aijuan Qu
Aims: The secreted glycoprotein leucine-rich α-2 glycoprotein 1 (LRG1) is implicated in atherosclerotic cardiovascular pathogenesis. Herein, we examined the relationship between LRG1 and cardiovascular events in patients with acute coronary syndrome (ACS). Methods and Results: Proteomics technology was used to identify the plasma LRG1 in ACS and chronic coronary syndrome (CCS) patients and control patients prospectively recruited in a multi-center investigative study. Plasma LRG1 was accessed in the 3 groups with sex- and age-matched healthy subjects serving as additional controls (n = 1820). Compared with both CCS and controls, ACS patients showed markedly elevated LRG1 levels (p<0.001) which were consistent in the Chui Yang Liu hospital (CYL) cohort (n=409) from another research center. Furthermore, among ACS patients, we evaluated the association of LRG1 with major adverse cardiovascular events (MACE), a composite of cardiac death, myocardial infarction, ischemic stroke, non-cardiovascular death, hospitalization for heart failure, recurrent angina pectoris and target vessel revascularization. After a median follow up of 1.23 (1.19-1.29) years, LRG1 was independently associated with increased MACE risk over 1 year (LRG1 tertile3 vs tertile1: HR: 4.35, 95% CI: 2.01-9.4, p=0.029) and 4-year (LRG1 tertile3 vs tertile1: HR:3.19, 95% CI 1.81-5.63, p< 0.001) after adjust for clinical variables, biomarkers and Grace 2.0 score. The results were similar in the UK cohort. Mediation analyses indicated that CRP partially mediated the association of LRG1 with MACE, with the mediation proportion being 13.4% (95% CI: 4.2-28.1%) in the derivation cohort and 43.3% (95%CI:13.4-123.2%) in the UK validation cohort, respectively. Besides, LRG1 was correlated with thin-cap fibroatheroma (p=0.007) and plaque rupture (p=0.02) in the culprit lesion detected by optical coherence tomography. Conclusion: LRG1 might be a novel and independent biomarker for cardiovascular events in patients presenting with ACS. LRG1 may provide prognostic information on the risk of recurrent cardiovascular events in the secondary prevention management of ACS and hold promise as a therapeutic target.